All In MedTech

Device Trial Radar · NCT07821112

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

A Phase II Study of Elderly and Frail Patients With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile® (ENDURANCE Trial)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Oct 2027

Study completion Oct 2029

Sponsor

Lead sponsor
University of California, IrvineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GT Medical Technologies, Inc.
First posted
Sep 15, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, open-label clinical trial determining feasibility, safety, and tolerability of GammaTile® in elderly or frail subjects with newly diagnosed or recurrent malignant gliomas.

Conditions

  • Glioma
  • Glioblastoma
  • GBM
  • Glioma, Malignant
  • Astrocytoma
  • Oligodendroglioma
  • Elderly Glioblastoma
  • Elderly GBM

Interventions

  • GammaTile®Device

    GammaTile is a bioabsorbable collagen tile embedded with cesium-131 radioactive seeds.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who were able to receive the GammaTile ImplantTime frame: 28 days
  2. Number of Participants with Treatment-related Adverse EventsTime frame: 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chao Family Comprehensive Cancer Center, University of California, Irvine

    Orange, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.